Vlerick Expertise in Healthcare

 

19 results Number of Results per Page
  1. Price of medication

    Medicines: how much should they cost?

    Although medical progress is allowing us to treat more and more diseases, innovative medicines tend to be expensive. Expenses are rising constantly in the healthcare sector as a result, putting accessibility and affordability under pressure. Which criteria does the Belgian Commission for Reimbursement of Medicines apply and what could be improved? These questions are answered in a study based on RIZIV data, in the framework of the Roche Chair at the Vlerick Healthcare Management Centre.

  2. Flexible working in hospitals

    Flexible working in hospitals: how to make it a success

    Flexible working is all the rage these days, and hospitals can't escape the trend either. The white paper ‘Flexible working in hospitals: OM and HRM perspective’ by our MINOZ research centre is the fruit of last year's efforts. It examines what flexible working means for the organisation and the employee, how the two perspectives can be brought into balance and which forms of flexible working are relevant for hospitals. Illustrated with practical examples, it offers food for thought for organisations which would like to introduce flexible working themselves.

  3. White paper priorities in healthcare

    Setting Priorities in Healthcare

    Healthcare organisations are under growing pressure to give patients better outcomes and add value for all stakeholders. And in recent years, there has been an increase in innovation across the sector – with the arrival of emerging technologies and pharmaceutical
    advances that have the potential to enhance the lives of patients around the world.

  4. IT roadmap for Belgian hospitals

    An IT roadmap for hospitals: one size does not fit all

    Digital technologies have become indispensable in the healthcare sector. They help to achieve better and cheaper healthcare. Policymakers are focusing strongly on eHealth and collaboration between the various players in the healthcare ecosystem. Belgian hospitals have already spent too long using IT purely as a support tool, however, with all the associated consequences. It is essential for them not to miss the boat. Professor Brecht Cardoen and professor Bjorn Cumps explain how a tool which was developed in collaboration with hospitals and their stakeholders can help.

  5. Hospital network formation

    Hospital networks: quo vadis?

    Hospitals are increasingly joining forces in networks of different types, sometimes with other healthcare players. This is an unmistakable trend, but forming networks is also an important strategic decision. How can hospitals ensure the right decisions are taken, both today and tomorrow, guaranteeing a robust, resilient and versatile organisation in the long run? Changes are rapidly succeeding one another, but who knows what healthcare will be like fifteen years from now and what the best set-up would be for these networks? No one can predict the future. However, despite all the uncertainties, a scenario analysis can help in the decision-making process.

  6. UCB

    Pharma and data as gospel

    Developing drugs is a time-consuming process. In order to speed it up, the Belgian biopharmaceuticals producer UCB has decided to switch to a data-driven organisation. It was necessary to ‘convert’ the entire company to achieve this, says CIO Herman De Prins.

  7. Innovative cancer treatments: how much are we willing to pay?

    One man in three and one woman in four will develop cancer before their 75th birthday. In Belgium, cancer is the second major cause of disease burden after cardiovascular diseases and it is unlikely this will change in the foreseeable future. Increasingly better but more expensive cancer therapies are becoming available. Needless to say, in these times of austerity, the public budget for cancer treatment is under pressure. How can we ensure all patients continue to have access to these expensive but potentially life-saving medicines at a price society can afford, while at the same time encouraging pharmaceutical companies to innovate?

  8. 3D printing: a laboratory for business model research

    What should established companies do when an innovative – and potentially disruptive – new technology appears on the scene? Vlerick Business School and Sirris collaborated to develop a framework linking technology and business models. When applied to the subject of 3D printers, their model led to a number of surprising insights.

  9. Digital strategy at Merck Sharp & Dohme

    The case takes us back to October 2009, and presents a key strategic challenge facing the senior management at Merck Sharp & Dohme (MSD) BeLux: crafting the organisation’s digital strategy for the marketing and sales of its human health products in Belgium and Luxembourg.

  10. The growing importance of traceability in the health care sector

    Faulty breast implant scandals, evolutions in the legal framework, counterfeit products and patient safety are all issues that have highlighted the importance of traceability in the health care sector. The Vlerick Healthcare Supply Chain Research Network analysed in which fields the various players in the supply chain can make the greatest profits thanks to a more efficient track-and-trace process. Moreover, the main drivers and obstacles were identified.

19 results Number of Results per Page